Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.57 |
| ▸ | FAP | Q12884 | 13/20 | 0.53 |
| ▸ | PREP | P48147 | 5/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31512419 | 0.79 | NSD2 (0.67) | NSD2 | |
| SCHEMBL6630664 | 0.78 | TACR3 (0.72) | — | |
| SCHEMBL12903049 | 0.76 | NSD2 (0.59) | NSD2FAPPREPDPP7CNR1 | |
| SCHEMBL30135587 | 0.75 | NSD2 (0.62) | NSD2FAPPREPDPP7PITRM1 | |
| SCHEMBL15129718 | 0.75 | NSD2 (0.62) | NSD2FAPPREPDPP7PITRM1 | |
| SCHEMBL8573837 | 0.74 | NSD2 (0.56) | NSD2FAPPREPCNR1CNR2 | |
| SCHEMBL5603305 | 0.74 | NSD2 (0.56) | NSD2FAPPREPDPP7CNR1 | |
| SCHEMBL21101481 | 0.74 | NSD2 (0.57) | NSD2FAPPREPDPP7CNR1 | |
| SCHEMBL24928106 | 0.73 | FAP (0.73) | FAPPREPDPP7 | |
| SCHEMBL20681090 | 0.73 | CNR1 (0.54) | NSD2FAPPREPDPP7CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | NSD2 2096/4885FAP 3352/4885PREP 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.